WO2012132747A1 - Liquid composition for oral cavity and method for stable addition of components to composition - Google Patents
Liquid composition for oral cavity and method for stable addition of components to composition Download PDFInfo
- Publication number
- WO2012132747A1 WO2012132747A1 PCT/JP2012/055170 JP2012055170W WO2012132747A1 WO 2012132747 A1 WO2012132747 A1 WO 2012132747A1 JP 2012055170 W JP2012055170 W JP 2012055170W WO 2012132747 A1 WO2012132747 A1 WO 2012132747A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- component
- composition
- plaque
- blended
- liquid oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
Definitions
- the present invention has an excellent effect of suppressing the adhesion of dental plaque to the tooth surface and the ability to sterilize mutans bacteria in dental plaque, and has improved appearance stability (no lip) and good palatability, and does not contain ethanol.
- the present invention relates to a liquid oral composition and a method for stabilizing and blending ingredients into the composition.
- Plaque suppression is important for the prevention of periodontal disease and caries, and oral compositions containing a bactericidal agent are widely used for the purpose of plaque suppression.
- a bactericidal agent are widely used for the purpose of plaque suppression.
- cationic fungicides are widely used because they have bactericidal effects on oral bacteria, plaque-inhibiting effects, and gingivitis improving effects.
- hydroxyethyl cellulose dimethyl diallylammonium chloride has a property of being easily adsorbed on the tooth surface, and a liquid oral composition capable of effectively suppressing plaque formation using this is disclosed in Patent Document 1 (Japanese Patent Laid-Open No. 2001-2001). No. 64137).
- Patent Document 2 Japanese Patent Document 1; JP 2001-139442 A, Patent Document 4; JP 2001-2001). 139443.
- a technology that stably mixes a cationic bactericide and hydroxyethyl cellulose dimethyl diallylammonium chloride into a liquid formulation that does not contain ethanol ensures appearance stability, and achieves both the effects of both components and the preference of the formulation. Is desired.
- the present invention has been made in view of the above circumstances, and is excellent in anti-plaque adhesion and sterilizing ability against mutans bacteria in plaque, and has improved appearance stability and good palatability.
- An object of the present invention is to provide a liquid oral composition that does not contain it, and a method for stabilizing and blending ingredients into the composition.
- the present inventor has formulated (A) a cationic bactericidal agent and (B) hydroxyethyl cellulose dimethyl diallylammonium chloride into a liquid oral composition substantially free of ethanol.
- (C) Anethole is blended such that (C) component / [(A) component + (B) component] is in a mass ratio of 0.1 to 10, and (D) polyhydric alcohol and / or ( E)
- a nonionic surfactant it has excellent anti-plaque effect on plaque adhesion and sterilizing ability of mutans bacteria in plaque, and also suppresses the occurrence of orientation of the preparation and improves the appearance stability over time. It has been found that a liquid preparation with high appearance stability and good palatability can be obtained, and the present invention has been made.
- the present applicant has formulated a liquid oral composition containing substantially no ethanol, a cationic disinfectant and a cationized cellulose, and a blend of propylene glycol, polyoxyethylene hydrogenated castor oil, and paraoxybenzoic acid ester.
- Japanese Patent Application No. 2010-280009 Japanese Patent Application No. 2011-148770 shows that the composition for oral cavity is excellent in the effect of suppressing the adhesion of plaque and the sterilizing ability of mutans bacteria in the plaque, as well as the antiseptic power and appearance stability of the preparation. Proposed).
- This composition for liquid oral cavity is excellent in appearance stability (no tilt) after storage at 5 ° C. for 1 month.
- Anethole is known to be used as a fragrance in oral compositions, but is effective for stabilizing and blending cationic bactericides and hydroxyethylcellulose dimethyl diallylammonium chloride into liquid oral compositions that do not contain ethanol, It is a new finding of the present inventor that high appearance stability with almost no orientation can be secured even after storage at 50 ° C. for 1 month, and that a liquid preparation having the above-mentioned special effects can be obtained.
- the present invention provides the following liquid oral composition and a method for stabilizing and blending ingredients into the composition.
- a liquid oral composition substantially free of ethanol is blended with (A) a cationic fungicide and (B) hydroxyethyl cellulose dimethyl diallylammonium chloride, and (C) anethole is added to component (C) / [(A).
- Component + (B) component] is used in a mass ratio of 0.1 to 10, and (D) a polyhydric alcohol and / or (E) a nonionic surfactant is blended.
- Liquid oral composition is used in a mass ratio of 0.1 to 10
- D a polyhydric alcohol and / or (E) a nonionic surfactant is blended.
- a liquid oral composition substantially free of ethanol is blended with (A) a cationic fungicide and (B) hydroxyethyl cellulose dimethyl diallylammonium chloride, and (C) anethole is added to component (C) / [(A).
- Component + (B) component] is used in a range of 0.1 to 10 as a mass ratio, and (D) a polyhydric alcohol and / or (E) a nonionic surfactant is blended, A method of stabilizing and blending the components (A) and (B) in the composition.
- a liquid oral composition substantially free of ethanol having excellent anti-plaque adhesion effect and sterilizing ability of mutans bacteria in dental plaque, improved appearance stability and good palatability Can be provided.
- the liquid oral composition of the present invention comprises (A) a cationic fungicide, (B) hydroxyethylcellulose dimethyl diallylammonium chloride, (C) anethole, (D) a polyhydric alcohol and / or (E) a nonionic surfactant. Contains agents.
- the cationic fungicide of the component (A) is an active ingredient for suppressing adhesion of plaque to the tooth surface and sterilizing mutans bacteria in the plaque.
- Specific examples include cetylpyridinium chloride, benzethonium chloride, and benzalkonium chloride. One of these can be used alone, or two or more can be used in combination. Of these, cetylpyridinium chloride is preferred in terms of bactericidal power, handling properties and usability.
- the blending amount of the cationic fungicide as component (A) is 0.01 to 0.1% (mass) of the whole composition from the viewpoint of suppressing adhesion of plaque to the tooth surface and sterilizing ability of mutans bacteria in the plaque. %. The same shall apply hereinafter.), In particular, 0.02 to 0.05% is preferable. If it is less than 0.01%, the effect of suppressing the adhesion of plaque to the tooth surface and the sterilizing ability of mutans bacteria in the plaque may not be satisfactorily exhibited. If it exceeds 0.1%, astringent taste, bitter taste, and off-flavor derived from the cationic fungicide may occur.
- (B) Hydroxyethyl cellulose dimethyl diallylammonium chloride is a cationic polymer, and is blended as an active ingredient for suppressing adhesion of plaque to the tooth surface.
- the component (B) together with the cationic germicide of the component (A) the effect of suppressing the adhesion of plaque to the tooth surface can be improved, and the mutans bacteria in the plaque can be effectively sterilized, By combining both effects, a high plaque formation inhibitory effect is achieved.
- a commercially available product can be used as hydroxyethyl cellulose dimethyl diallylammonium chloride, and examples thereof include the following.
- ⁇ Cell coat L-200 (manufactured by Akzo Nobel): Nitrogen content 0.1-3%, 2% aqueous solution viscosity 30-3,000 mPa ⁇ s (BH Brookfield viscometer, rotor No. 2, 20 revolutions, 21 ° C., measurement time 1 minute)
- ⁇ Cell coat H-100 (manufactured by Akzo Nobel): Nitrogen content is 1.0%, 2% aqueous solution viscosity is 500-2,750 mPa ⁇ s (BH type Brookfield viscometer, rotor No. 2, 20 revolutions, 21 ° C., measuring time 1 minute)
- the blending amount of component (B) hydroxyethylcellulose dimethyl diallylammonium chloride is preferably 0.005 to 0.5%, particularly 0.01 to 0.05% of the total composition. If it is less than 0.005%, the plaque adhesion inhibiting effect may not be satisfactorily exhibited. If it exceeds 0.5%, orientation may occur and appearance stability (no orientation) may be impaired, and astringency, bitterness, and off-taste derived therefrom may occur, resulting in a decrease in the feeling of use.
- Component (C) Anethole is blended as a stabilizer.
- orientation can be suppressed over time and appearance stability can be improved, and the feeling of use (astringency, bitterness, tastelessness) can also be improved.
- the blending amount of anethole is preferably 0.01 to 0.2%, particularly preferably 0.01 to 0.1% of the whole composition. If the blending amount is less than 0.01%, the appearance stability (no tilt) may not be satisfactorily improved. In addition, the feeling of use (astringency, bitterness, tastelessness) may not be improved. If it exceeds 0.2%, the appearance stability (no tilt) may be impaired, and the feeling of use (taste) may be reduced.
- component (C) / [component (A) + component (B)] is 0.1 to 10, and preferably 0.2 to 2, as a mass ratio.
- (C) By mix
- (A) and (B) component can be stabilized and mix
- (D) and (E) component may mix
- Examples of the (D) polyhydric alcohol include propylene glycol, glycerin, xylitol, sorbit, polyethylene glycol such as ethylene glycol and polyethylene glycol 400, polypropylene glycol, malt, lactit, and the like. A mixture of more than one can be used.
- (E) As a nonionic surfactant what is normally mix
- polyoxyethylene hydrogenated castor oil having an average addition mole number of ethylene oxide of 60 to 100 moles, an alkyl group having 16 (cetyl) to 18 (stearyl) carbon atoms and an average addition mole number of ethylene oxide of 20 to 40 moles.
- polyoxyethylene hydrogenated castor oil is preferable from the viewpoint of sufficiently exerting the adhesion inhibitory effect of plaque on the tooth surface and the sterilizing ability of mutans bacteria in the plaque, and the appearance stability (no orientation),
- ethylene oxide having an average added mole number of 60 to 100 moles is preferred. When the average added mole number of ethylene oxide is less than 60 moles, orientation may occur in a 50 ° C. stored product and appearance stability (no orientation) may be impaired, and those exceeding 100 moles are generally not commercially available.
- NIKKOL HCO Polyoxyethylene hydrogenated castor oil
- Emalex HC system manufactured by Nihon Emulsion Co., Ltd.
- UNIOX HC system manufactured by NOF Corporation
- the nonionic surfactant (E) When the nonionic surfactant (E) is blended, it is preferable to add 0.3 to 2%, particularly 0.5 to 1% of the whole composition. If it is less than 0.3%, the appearance stability (no orientation) may not be improved. If it exceeds 2%, the adhesion of dental plaque to the tooth surface and the ability to sterilize mutans bacteria in the plaque will be satisfactorily exhibited. May not be. Further, the feeling of use may be reduced.
- the liquid oral composition of the present invention can be prepared and applied as a mouthwash, a mouth freshener, a liquid dentifrice used by brushing with a toothbrush, a dentifrice gel, etc. Suitable as an agent.
- an appropriate known arbitrary component can be blended in addition to the above components within a range not impairing the effects of the present invention.
- wetting agents, thickeners, preservatives, sweeteners, fragrances other than component (C), surfactants other than component (E), active ingredients other than components (A) and (B), colorants, pH A regulator or the like can be added.
- polishing agent can be added.
- the thickener include xanthan gum, sodium alginate, polyvinyl alcohol, hydroxyethyl cellulose, carrageenan, carboxymethyl cellulose sodium, polyvinyl pyrrolidone and the like.
- the blending amount of these thickeners is usually 0 to 3% of the whole composition.
- Examples of the preservative include parabens such as sodium benzoate, methyl paraben, ethyl paraben, propyl paraben, and butyl paraben, cetylpyridinium chloride, alkyldiaminoethylglycine hydrochloride, potassium sorbate, and the like.
- Examples of the sweetening agent include saccharin, saccharin sodium, steviosite, sucralose, reduced palatinose, erythritol, aspartame and the like.
- Perfumes other than anethole such as peppermint oil, spearmint oil, eucalyptus oil, wintergreen oil, clove oil, thyme oil, sage oil, cardamom oil, rosemary oil, marjoram oil, lemon oil, nutmeg oil, lavender oil
- Natural essential oils such as paracres oil, and l-menthol, l-carvone, cinnamic aldehyde, orange oil, 1,8-cineole, methyl salicylate, eugenol, thymol, linalool, limonene, menthone, menthyl acetate, citral, camphor,
- Perfume ingredients contained in the above natural essential oils such as borneol, pinene, spiranthol, etc., as well as ethyl acetate, ethyl butyrate, isoamyl acetate, hexanal, hexenal, methyl anthranilate,
- anionic surfactants such as sodium lauryl sulfate, lauroylmethyl taurine, acylamino acid salts, sodium dodecylbenzenesulfonate, Anionic surfactants such as ⁇ -sulfo fatty acid alkyl ester sodium and alkyl phosphate ester salts, betaine acetate type amphoteric surfactants such as alkyldimethylaminoacetic acid betaine and fatty acid amidopropyldimethylaminoacetic acid betaine, N-fatty acid acyl- Examples include imidazoline type amphoteric surfactants such as N-carboxymethyl-N-hydroxyethylethylenediamine salt, and amino acid type surfactants such as N-fatty acid acyl-L-alginate salts.
- the blending amount is usually 0 to 5%, particularly preferably
- the active ingredient examples include bactericides such as chlorhexidine hydrochloride and alkyldiaminoethylglycine hydrochloride, anti-inflammatory agents such as tranexamic acid, epsilon-aminocaproic acid, allantoin, allantoinchlorohydroxyaluminum, allantoindihydroxyaluminum, dextranase, amylase, Enzymes such as protease, mutanase, lysozyme, lytic enzyme, lytechenzyme, fluoride such as sodium fluoride, sodium monofluorophosphate, stannous fluoride, vitamin C such as azulene, lysozyme chloride, ascorbic acid, dihydrocholesterol , Glycyrrhetin salts, Glycyrrhetinic acids, Hydrocholesterol, Chlorophyll, Copper chlorophyllin sodium, Thyme, Ogon, Clove, Hamamelis It
- a highly safe water-soluble pigment such as Blue No. 1, Green No. 3, Yellow No. 4, Red No. 105
- pH adjusters include phthalic acid, phosphoric acid, citric acid, succinic acid, acetic acid, fumaric acid, malic acid, carbonic acid and their potassium salts, sodium salts or ammonium salts, ribonucleic acid and salts thereof, sodium hydroxide, etc. 1 type or 2 or more types can be used, and what combined phosphoric acid and a citric acid, and those sodium salts is especially preferable.
- the liquid oral composition of the present invention preferably adjusts the pH at 25 ° C. to 5.5 to 8.5, and sodium dihydrogen phosphate and sodium monohydrogen phosphate as pH adjusters in the vicinity thereof.
- a combination of citric acid and sodium citrate can be used.
- the compounding quantity can be 60% or more, especially 70% or more.
- the liquid oral composition of the present invention is substantially free of ethanol.
- “substantially free of ethanol” means that the amount of ethanol in the composition is preferably 100 ppm or less, more preferably 50 ppm or less, particularly preferably 10 ppm or less, based on the total composition. The value is 0 ppm.
- the liquid oral composition of the present invention contains no ethanol. However, since the raw material-derived ethanol may be contained in a small amount in the fragrance compounded in the composition, these reasons are taken into consideration. In addition to ethanol contained in trace amounts in perfume and the like, it does not contain ethanol.
- Liquid oral compositions having the compositions shown in Tables 1 to 4 were prepared by a conventional method and evaluated as follows. The results are shown in Tables 1 to 4.
- Evaluation criteria for plaque adhesion suppression effect A: Average value of a value is less than 5 ⁇ : Average value of a value is 5 or more and less than 7.5 ⁇ : Average value of a value is 7.5 or more and less than 10 ⁇ : Average value of a value is 10 or more
- a hydroxyapatite disk (diameter 7 mm ⁇ height 3.5 mm) as an attachment carrier was attached to a rotating disk (rotated at about 80 rpm) in the culture tank, and dental plaque was artificially formed on the surface thereof.
- the culture by the above method was carried out for 14 days, and the following treatment was carried out for the latter 7 days. That is, 3 times a day, the hydroxyapatite disk to which plaque adheres is taken out of the culture tank, each is transferred to each petri dish (diameter 25 mm ⁇ height 14 mm), and the test composition 5 g (Example and Comparative Example) is used for 30 seconds. Soaked.
- the plaque was transferred to a test tube (diameter 13 mm ⁇ 100 mm) to which 4 mL of physiological saline was added in order to evaluate the bactericidal activity of mutans bacteria in the plaque of the test composition.
- ultrasonic disruption 200 ⁇ A output for 10 seconds
- serial dilution 10-fold dilution for 6 stages
- the plate medium was anaerobically cultured (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% hydrogen) until colonies could be confirmed with the naked eye. After counting the number of colonies in each plate medium, the number of viable bacteria was calculated. Further, as a control, the same treatment was performed using purified water instead of the test composition, and the number of viable bacteria in the plaque was calculated. The ratio of the viable count of those treated with each test composition when the viable count of those treated with purified water was taken as 100% was measured and indicated by the following criteria. Evaluation criteria: ⁇ : Number of remaining viable bacteria less than 1% ⁇ : Number of remaining viable bacteria 1% or more and less than 10% ⁇ : Number of remaining viable bacteria 10% or more and less than 50% ⁇ : Number of remaining viable bacteria 50% or more
- THBHM composition expressed in mass per liter
- Todd Hewit Broth Becton and Dickinso n company
- 30g / L Hemin Sigma Aldrich
- Vitamin K manufactured by Wako Pure Chemical Industries
- Purified water Residue (Measured up so that the total amount becomes 1 L.)
- Appearance stability evaluation method The sample (liquid oral composition) is filled into a colorless and transparent PET container (manufactured by Yoshino Kogyo Co., Ltd.) having a filled volume of 500 mL, and stored in a 50 ° C. constant temperature bath (manufactured by Sanyo Electric Co., Ltd., MPR-311) for one month. The appearance stability was visually determined according to the following criteria. Appearance stability evaluation criteria: A: No orientation is observed even when shaken. ⁇ : Although very small orientation is observed when shaken, it is at a level with no problem. ⁇ : Slight orientation is observed. X: Considerable orientation is recognized.
- the main raw materials used in each example are as follows.
- the perfume composition A is as shown in Tables 5 to 11.
- Cetylpyridinium chloride manufactured by Wako Pure Chemical Industries, Ltd.
- Benzethonium chloride Highamine 1622: Lonza Japan
- Hydroxyethylcellulose dimethyldiallylammonium chloride (trade name Cellcoat L-200: manufactured by Akzo Nobel)
- Leogard KGP O- [2-hydroxy-3- (trimethylammonio) propyl] hydroxyethylcellulose chloride: manufactured by Lion Corporation)
- Anethole manufactured by Wako Pure Chemical Industries
- Polyoxyethylene 100) hydrogenated castor oil (Nikko Chemicals)
- Polyoxyethylene 60
- hydrogenated castor oil (Nikko Chemicals)
- Propylene glycol (Asahi Glass Co., Ltd.)
- Glycerin 85%, Sakamoto Pharmaceutical Co., Ltd.)
- compositions in which the components (A) and (B) are blended (C) anethole, or (D) a polyhydric alcohol and (E) a nonionic surfactant are lacking (Comparative Examples 3 and 5), C) When the ratio of anethole to the components (A) and (B) is inadequate (Comparative Example 4), neither occurrence of orientation can be suppressed and appearance stability is inferior. Even if a known fragrance was blended, the orientation could not be suppressed.
- the composition of the present invention (Example) is excellent in plaque adhesion inhibiting effect and sterilizing effect of mutans bacteria in plaque, and has a good appearance with almost no orientation even when stored at 50 ° C. for 1 month. It turned out that it became stable, and also there was no astringency, bitterness, and unpleasant taste, and the feeling of use was also good.
- liquid oral compositions of the following formulation examples were similarly prepared and evaluated. These compositions were excellent in plaque adhesion inhibitory effect, sterilizing ability of mutans bacteria in plaque, appearance stability and feeling of use.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、上記事情に鑑みなされたもので、歯垢の付着抑制効果及び歯垢中のミュータンス菌殺菌力に優れる上、外観安定性が向上し嗜好性も良好な、エタノールを実質的に含有しない液体口腔用組成物及び該組成物への成分の安定化配合方法を提供することを目的とする。 Therefore, a technology that stably mixes a cationic bactericide and hydroxyethyl cellulose dimethyl diallylammonium chloride into a liquid formulation that does not contain ethanol, ensures appearance stability, and achieves both the effects of both components and the preference of the formulation. Is desired.
The present invention has been made in view of the above circumstances, and is excellent in anti-plaque adhesion and sterilizing ability against mutans bacteria in plaque, and has improved appearance stability and good palatability. An object of the present invention is to provide a liquid oral composition that does not contain it, and a method for stabilizing and blending ingredients into the composition.
〔I〕
エタノールを実質的に含有しない液体口腔用組成物に、(A)カチオン性殺菌剤及び(B)ヒドロキシエチルセルロースジメチルジアリルアンモニウムクロリドを配合すると共に、(C)アネトールを(C)成分/[(A)成分+(B)成分]が質量比として0.1~10となる範囲で併用し、かつ(D)多価アルコール及び/又は(E)非イオン性界面活性剤を配合したことを特徴とする液体口腔用組成物。
〔II〕
エタノールを実質的に含有しない液体口腔用組成物に、(A)カチオン性殺菌剤及び(B)ヒドロキシエチルセルロースジメチルジアリルアンモニウムクロリドを配合すると共に、(C)アネトールを(C)成分/[(A)成分+(B)成分]が質量比として0.1~10となる範囲で併用し、かつ(D)多価アルコール及び/又は(E)非イオン性界面活性剤を配合し、前記液体口腔用組成物に(A)及び(B)成分を安定化配合する方法。 Accordingly, the present invention provides the following liquid oral composition and a method for stabilizing and blending ingredients into the composition.
[I]
A liquid oral composition substantially free of ethanol is blended with (A) a cationic fungicide and (B) hydroxyethyl cellulose dimethyl diallylammonium chloride, and (C) anethole is added to component (C) / [(A). Component + (B) component] is used in a mass ratio of 0.1 to 10, and (D) a polyhydric alcohol and / or (E) a nonionic surfactant is blended. Liquid oral composition.
[II]
A liquid oral composition substantially free of ethanol is blended with (A) a cationic fungicide and (B) hydroxyethyl cellulose dimethyl diallylammonium chloride, and (C) anethole is added to component (C) / [(A). Component + (B) component] is used in a range of 0.1 to 10 as a mass ratio, and (D) a polyhydric alcohol and / or (E) a nonionic surfactant is blended, A method of stabilizing and blending the components (A) and (B) in the composition.
・セルコートL-200(アクゾノーベル(株)製):
窒素含有量が0.1~3%で、2%水溶液粘度が30~3,000mPa・s(BH型ブルックフィールド粘度計、ローターNo.2、20回転、21℃、測定時間1分)
・セルコートH-100(アクゾノーベル(株)製):
窒素含有量が1.0%で、2%水溶液粘度が500~2,750mPa・s(BH型ブルックフィールド粘度計、ローターNo.2、20回転、21℃、測定時間1分) A commercially available product can be used as hydroxyethyl cellulose dimethyl diallylammonium chloride, and examples thereof include the following.
・ Cell coat L-200 (manufactured by Akzo Nobel):
Nitrogen content 0.1-3%, 2% aqueous solution viscosity 30-3,000 mPa · s (BH Brookfield viscometer, rotor No. 2, 20 revolutions, 21 ° C., measurement time 1 minute)
・ Cell coat H-100 (manufactured by Akzo Nobel):
Nitrogen content is 1.0%, 2% aqueous solution viscosity is 500-2,750 mPa · s (BH type Brookfield viscometer, rotor No. 2, 20 revolutions, 21 ° C., measuring time 1 minute)
(C)アネトールの配合量は、組成物全体の0.01~0.2%、特に0.01~0.1%が好ましい。配合量が0.01%未満では、外観安定性(オリのなさ)を満足に向上できない場合がある。また、使用感(渋味・苦味・異味のなさ)を改善できない場合がある。0.2%を超えると、外観安定性(オリのなさ)を損ねたり、使用感(異味)が低下する場合がある。 Component (C) Anethole is blended as a stabilizer. By blending Anethole, orientation can be suppressed over time and appearance stability can be improved, and the feeling of use (astringency, bitterness, tastelessness) can also be improved.
(C) The blending amount of anethole is preferably 0.01 to 0.2%, particularly preferably 0.01 to 0.1% of the whole composition. If the blending amount is less than 0.01%, the appearance stability (no tilt) may not be satisfactorily improved. In addition, the feeling of use (astringency, bitterness, tastelessness) may not be improved. If it exceeds 0.2%, the appearance stability (no tilt) may be impaired, and the feeling of use (taste) may be reduced.
(D)成分の多価アルコールを配合する場合は、組成物全体の2~20%、特に2~15%添加することが好ましい。2%未満では外観安定性(オリのなさ)を満足に改善できない場合がある。20%を超えると多価アルコール由来の異味が生じ、使用感(渋味・苦味・異味のなさ)が損なわれる場合がある。 Examples of the (D) polyhydric alcohol include propylene glycol, glycerin, xylitol, sorbit, polyethylene glycol such as ethylene glycol and polyethylene glycol 400, polypropylene glycol, malt, lactit, and the like. A mixture of more than one can be used.
When blending the component (D) polyhydric alcohol, it is preferable to add 2 to 20%, particularly 2 to 15% of the total composition. If it is less than 2%, the appearance stability (no tilt) may not be satisfactorily improved. If it exceeds 20%, an off-taste derived from a polyhydric alcohol is produced, and the feeling of use (astringency, bitterness, lack of off-taste) may be impaired.
・ポリオキシエチレン硬化ヒマシ油
日光ケミカルズ社製のNIKKOL HCO系、日本エマルジョン社製のエマレックスHC系、日油社製のユニオックスHC系等
・ポリオキシエチレンアルキルエーテル
日本エマルジョン株式会社製のエマレックス100系、エマレックス600系等
・デカグリセリンモノ脂肪酸エステル
日光ケミカルズ社製のNIKKOL Decagln系、三菱化学フーズ社製のリョートー(登録商標)ポリグリエステルDシリーズ等 Specifically, the following commercially available products can be used.
・ Polyoxyethylene hydrogenated castor oil NIKKOL HCO system manufactured by Nikko Chemicals, Emalex HC system manufactured by Nihon Emulsion Co., Ltd., UNIOX HC system manufactured by NOF Corporation, etc. ・ Polyoxyethylene alkyl ether Emalex manufactured by Nihon Emulsion Co., Ltd. 100 series, Emalex 600 series, etc. Decaglycerin monofatty acid ester NIKKOL Decagln series manufactured by Nikko Chemicals, Ryoto (registered trademark) polyglycerester D series manufactured by Mitsubishi Chemical Foods, etc.
本発明組成物には、その剤型等に応じて、本発明の効果を損なわない範囲で上記成分以外に適宜な公知の任意成分を配合することができる。例えば、湿潤剤、増粘剤、防腐剤、甘味剤、(C)成分以外の香料、(E)成分以外の界面活性剤、(A)及び(B)成分以外の有効成分、着色料、pH調整剤等を配合できる。なお、研磨剤は配合しなくてもよい。 The liquid oral composition of the present invention can be prepared and applied as a mouthwash, a mouth freshener, a liquid dentifrice used by brushing with a toothbrush, a dentifrice gel, etc. Suitable as an agent.
According to the dosage form and the like of the present invention, an appropriate known arbitrary component can be blended in addition to the above components within a range not impairing the effects of the present invention. For example, wetting agents, thickeners, preservatives, sweeteners, fragrances other than component (C), surfactants other than component (E), active ingredients other than components (A) and (B), colorants, pH A regulator or the like can be added. In addition, it is not necessary to mix | blend an abrasive | polishing agent.
増粘剤としては、例えばキサンタンガム、アルギン酸ナトリウム、ポリビニルアルコール、ヒドロキシエチルセルロース、カラギナン、カルボキシメチルセルロースナトリウム、ポリビニルピロリドン等が挙げられる。これら増粘剤の配合量は、通常、組成物全体の0~3%である。 What is necessary is just to mix | blend the polyhydric alcohol of the said (D) component as a wetting agent.
Examples of the thickener include xanthan gum, sodium alginate, polyvinyl alcohol, hydroxyethyl cellulose, carrageenan, carboxymethyl cellulose sodium, polyvinyl pyrrolidone and the like. The blending amount of these thickeners is usually 0 to 3% of the whole composition.
甘味剤としては、サッカリン、サッカリンナトリウム、ステビオサイト、スクラロース、還元パラチノース、エリスリトール、アスパルテーム等が挙げられる。 Examples of the preservative include parabens such as sodium benzoate, methyl paraben, ethyl paraben, propyl paraben, and butyl paraben, cetylpyridinium chloride, alkyldiaminoethylglycine hydrochloride, potassium sorbate, and the like.
Examples of the sweetening agent include saccharin, saccharin sodium, steviosite, sucralose, reduced palatinose, erythritol, aspartame and the like.
pH調整剤としては、フタル酸、リン酸、クエン酸、コハク酸、酢酸、フマル酸、リンゴ酸、炭酸やそれらのカリウム塩、ナトリウム塩又はアンモニウム塩、リボ核酸やその塩類、水酸化ナトリウムなどの1種又は2種以上を用いることができ、特にリン酸、クエン酸とそれらのナトリウム塩とを組み合わせたものが好ましい。この場合、本発明の液体口腔用組成物は、25℃におけるpHを5.5~8.5に調整することが好ましく、この付近のpH調整剤としてリン酸二水素ナトリウムとリン酸一水素ナトリウム、あるいはクエン酸とクエン酸ナトリウムとを組み合わせたものを用いることができる。 As a colorant, a highly safe water-soluble pigment such as Blue No. 1, Green No. 3, Yellow No. 4, Red No. 105 can be added.
Examples of pH adjusters include phthalic acid, phosphoric acid, citric acid, succinic acid, acetic acid, fumaric acid, malic acid, carbonic acid and their potassium salts, sodium salts or ammonium salts, ribonucleic acid and salts thereof, sodium hydroxide, etc. 1 type or 2 or more types can be used, and what combined phosphoric acid and a citric acid, and those sodium salts is especially preferable. In this case, the liquid oral composition of the present invention preferably adjusts the pH at 25 ° C. to 5.5 to 8.5, and sodium dihydrogen phosphate and sodium monohydrogen phosphate as pH adjusters in the vicinity thereof. Alternatively, a combination of citric acid and sodium citrate can be used.
表1~4に示す組成の液体口腔用組成物を常法により調製し、下記評価を行った。結果を表1~4に示す。 [Examples and Comparative Examples]
Liquid oral compositions having the compositions shown in Tables 1 to 4 were prepared by a conventional method and evaluated as follows. The results are shown in Tables 1 to 4.
24ウェルマルチプレート中に液体口腔用組成物をそれぞれ2mLずつ入れ、鏡面研磨したペンタックス社製ハイドロキシアパタイト板(半径0.35cm×高さ0.35cm 以下、HAP板と記す。)3枚を30秒間浸漬した。
24ウェルマルチプレート中に、ストレプトコッカス ミュータンス(Streptococcus mutans)10449株を波長660nmでの濁度が0.35になるように分散させた緩衝液*1を2mL入れ、上記HAP板を3枚ずつ浸漬し、37℃で2時間静置して菌を付着させた。次に、上記HAP板を取り出して滅菌水で洗浄後、液体培地*22mLに洗浄したHAP板を3枚ずつ37℃で8時間浸漬し、付着菌を培養した。蒸留水で洗浄後、歯垢染色液で染色し、色差計でa値を測定し、上記3枚の平均値を算出した。評価基準は以下の通りである。 (I) Plaque adhesion inhibitory effect Pentax hydroxyapatite plate (radius 0.35 cm × height 0.35 cm or less, HAP plate) 3) Soaked 3 sheets for 30 seconds.
In a 24-well multiplate, add 2 mL of buffer solution * 1 in which Streptococcus mutans 10449 strain is dispersed so that the turbidity at a wavelength of 660 nm is 0.35, and immerse the above HAP plates three by three. And left to stand at 37 ° C. for 2 hours to allow the bacteria to adhere. Next, the HAP plate was taken out and washed with sterilized water, and then the HAP plates washed in 2 mL of liquid medium * 2 were immersed in 3 pieces at 37 ° C. for 8 hours to culture adherent bacteria. After washing with distilled water, it was stained with a plaque staining solution, the a value was measured with a color difference meter, and the average value of the three sheets was calculated. The evaluation criteria are as follows.
◎:a値の平均値が5未満
○:a値の平均値が5以上7.5未満
△:a値の平均値が7.5以上10未満
×:a値の平均値が10以上 Evaluation criteria for plaque adhesion suppression effect:
A: Average value of a value is less than 5 ○: Average value of a value is 5 or more and less than 7.5 Δ: Average value of a value is 7.5 or more and less than 10 ×: Average value of a value is 10 or more
塩化カリウム(KCl)3.37g、リン酸2水素カリウム(KH2PO4)0.14g、塩化カルシウム(CaCl2)0.11g、塩化マグネシウム(MgCl2)0.02gを800mLの精製水に溶かして、水酸化カリウム(KOH)でpHを7.0に調整し、精製水で全量が1Lになるようにメスアップした。
*2:液体培地の組成
トリプチック ソイ ブロス(Tryptic Soy Broth)3g、サッカロース(Sucrose)0.5gに精製水100mLを加えて溶解させた。 * 1: Composition of buffer solution 3.37 g of potassium chloride (KCl), 0.14 g of potassium dihydrogen phosphate (KH 2 PO 4 ), 0.11 g of calcium chloride (CaCl 2 ), 0.02 g of magnesium chloride (MgCl 2 ) Was dissolved in 800 mL of purified water, pH was adjusted to 7.0 with potassium hydroxide (KOH), and the volume was adjusted to 1 L with purified water.
* 2: Composition of liquid medium 100 mL of purified water was dissolved in 3 g of Tryptic Soy Broth and 0.5 g of Sucrose.
歯垢中のミュータンス菌殺菌力の評価方法:
ライオン株式会社オーラルケア研究所において継代保存(凍結保存)してあったアクチノマイセス ナイスランディー(Actinomyces naeslundii)T14V株、フゾバクテリウム ニュークレアタム(Fusobacterium nucleatum)ATCC10953株、ポルフィロモーナス ジンジバリス(Porphyromonas gingivalis)W50株、ストレプトコッカス ミュータンス(Streptococcus mutans)ATCC25175株の各菌液40μLをそれぞれ、121℃で15分間オートクレーブした5mg/Lヘミン(シグマ アルドリッチ社製)及び1mg/L ビタミンK(和光純薬工業社製)を含むトッドへーウィットブロース(Becton and Dickinson社製)(THBHM*3)4mLに添加し、37℃で一晩嫌気培養(80vol%窒素、10vol%二酸化炭素、10vol%水素)した。培養後、各菌液(4種)から300μLを採取し、それぞれ30mLのTHBHMに添加し、更に一晩培養した。再培養後、各菌液を遠心分離(10,000rpm、10min)し、上清を廃棄した。各沈渣(細菌)に対して121℃で15分間オートクレーブしたベイサルメディウムムチン培地(BMM*4)を添加し再懸濁した後、予めBMM1,000mLを入れた培養槽(直径140mm×高さ200mm)に、上記各菌数がそれぞれ1×107個/mLになるように接種し、攪拌子(直径10mm×長さ51mm)を用いて攪拌(約100rpmで回転)しながら、37℃、嫌気条件下(95vol%窒素、5vol%二酸化炭素)で一晩培養した。その後、BMMを100mL/hの速度で供給すると共に、同速度で培養液を排出した。上記培養槽から排出された培養液は、液量が300mLに保たれる別の培養槽(直径90mm×高さ190mm)に連続的に供給した。 (II) Mutant bacteria bactericidal power in dental plaque Evaluation method of mutans bacteria bactericidal power in dental plaque:
Actinomyces naeslundii T14V strain, Fusobacterium nucleatum ATCC10953 strain, Porphyromonas gingivalis (Porphylomonas gingivalis) (Porphyromonas gingivalis) ) 5 mg / L hemin (manufactured by Sigma Aldrich) and 1 mg / L vitamin K (Wako Pure Chemical Industries, Ltd.) obtained by autoclaving 40 μL of each bacterial solution of W50 strain, Streptococcus mutans ATCC25175 strain at 121 ° C. for 15 minutes, respectively Todd Hewitt Broth (Becton and Dicki) It was added son, Inc.) (in THBHM * 3) 4mL, overnight anaerobically cultured at 37 ° C. (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% of hydrogen) was. After culture, 300 μL was collected from each bacterial solution (4 types), added to 30 mL of THBHM, and further cultured overnight. After re-culture, each bacterial solution was centrifuged (10,000 rpm, 10 min), and the supernatant was discarded. A basal medium mucin medium (BMM * 4 ) autoclaved at 121 ° C. for 15 minutes was added to each sediment (bacteria) and resuspended, followed by a culture tank (diameter 140 mm × height 200 mm) containing 1,000 mL of BMM in advance. And inoculating so that the number of each bacterium is 1 × 10 7 cells / mL, and stirring with a stirrer (diameter 10 mm × length 51 mm) (rotating at about 100 rpm) at 37 ° C. under anaerobic conditions The cells were cultured overnight (95 vol% nitrogen, 5 vol% carbon dioxide) overnight. Thereafter, BMM was supplied at a rate of 100 mL / h, and the culture solution was discharged at the same rate. The culture medium discharged from the culture tank was continuously supplied to another culture tank (diameter 90 mm × height 190 mm) whose liquid volume was maintained at 300 mL.
上記方法による培養は14日間行い、後半の7日間は次に示す処置を行った。即ち、1日3回、歯垢が付着したハイドロキシアパタイトディスクを培養槽から取り出し、それぞれを各シャーレ(直径25mm×高さ14mm)に移し、試験組成物5g(実施例及び比較例)で30秒間浸漬した。その後、生理食塩水5gで3回洗浄後、再び培養槽内に戻した。同操作は総計7回実施した。
培養終了時には、試験組成物の歯垢中のミュータンス菌殺菌力を評価するため、歯垢を4mLの生理食塩水を添加した試験管(直径13mm×100mm)に移した。直ちに超音波破砕(200μAの出力で10秒間)、段階希釈(10倍希釈を6段階)を行い、常法で作製したバシトラシン添加Mitis-Salivarius寒天平板培地*5に各菌液を塗沫した。上記平板培地は、肉眼でコロニーが確認できるまで嫌気培養(80vol%窒素、10vol%二酸化炭素、10vol%水素)した。各平板培地のコロニー数をカウント後、生菌数を算出した。また、対照として試験組成物の代わりに精製水を用いて同様の処置をし、歯垢中の生菌数を算出した。精製水で処置したものの生菌数を100%としたときの各試験組成物で処置したものの生菌数の割合を測定し、以下の基準で示した。
評価基準:
◎:残存生菌数1%未満
○:残存生菌数1%以上10%未満
△:残存生菌数10%以上50%未満
×:残存生菌数50%以上 A hydroxyapatite disk (diameter 7 mm × height 3.5 mm) as an attachment carrier was attached to a rotating disk (rotated at about 80 rpm) in the culture tank, and dental plaque was artificially formed on the surface thereof.
The culture by the above method was carried out for 14 days, and the following treatment was carried out for the latter 7 days. That is, 3 times a day, the hydroxyapatite disk to which plaque adheres is taken out of the culture tank, each is transferred to each petri dish (diameter 25 mm × height 14 mm), and the test composition 5 g (Example and Comparative Example) is used for 30 seconds. Soaked. Then, after washing 3 times with 5 g of physiological saline, it was returned to the culture tank again. The same operation was performed seven times.
At the end of culture, the plaque was transferred to a test tube (diameter 13 mm × 100 mm) to which 4 mL of physiological saline was added in order to evaluate the bactericidal activity of mutans bacteria in the plaque of the test composition. Immediately, ultrasonic disruption (200 μA output for 10 seconds) and serial dilution (10-fold dilution for 6 stages) were performed, and each bacterial solution was smeared on a bacitracin-added Mitis-Salivarius agar plate medium * 5 prepared by a conventional method. The plate medium was anaerobically cultured (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% hydrogen) until colonies could be confirmed with the naked eye. After counting the number of colonies in each plate medium, the number of viable bacteria was calculated. Further, as a control, the same treatment was performed using purified water instead of the test composition, and the number of viable bacteria in the plaque was calculated. The ratio of the viable count of those treated with each test composition when the viable count of those treated with purified water was taken as 100% was measured and indicated by the following criteria.
Evaluation criteria:
◎: Number of remaining viable bacteria less than 1% ○: Number of remaining viable bacteria 1% or more and less than 10% Δ: Number of remaining viable bacteria 10% or more and less than 50% ×: Number of remaining viable bacteria 50% or more
トッドへーウィットブロース(Becton and Dickinso
n社製): 30g/L
ヘミン(シグマ アルドリッチ社製): 5mg/L
ビタミンK(和光純薬工業社製): 1mg/L
精製水: 残
(全量が1Lになるようにメスアップした。) * 3: THBHM composition (expressed in mass per liter)
Todd Hewit Broth (Becton and Dickinso
n company): 30g / L
Hemin (Sigma Aldrich): 5mg / L
Vitamin K (manufactured by Wako Pure Chemical Industries): 1mg / L
Purified water: Residue (Measured up so that the total amount becomes 1 L.)
プロテオースペプトン(Becton and Dickinson社製
): 2g/L
トリプトン(Becton and Dickinson社製):
1g/L
ムチン(シグマ アルドリッチ社製): 2.5g/L
ヘミン(シグマ アルドリッチ社製): 1mg/L
ビタミンK(和光純薬工業社製): 0.2mg/L
KCl(和光純薬工業社製): 0.5g/L
システイン(和光純薬工業社製): 0.1g/L
精製水: 残
(全量が1Lになるようにメスアップした。) * 4: BMM composition (expressed in mass per liter)
Proteose peptone (Becton and Dickinson): 2g / L
Tryptone (Becton and Dickinson):
1g / L
Mucin (Sigma Aldrich): 2.5g / L
Hemin (Sigma Aldrich): 1mg / L
Vitamin K (manufactured by Wako Pure Chemical Industries, Ltd.): 0.2mg / L
KCl (manufactured by Wako Pure Chemical Industries): 0.5g / L
Cysteine (manufactured by Wako Pure Chemical Industries): 0.1 g / L
Purified water: Residue (Measured up so that the total amount becomes 1 L.)
1リットル中の組成
Mitis-Salivarius Agar
(Becton and Dickinson社製):90g/L
バシトラシン(シグマ アルドリッチ社製): 200U/L
(バシトラシンは予め1,000倍濃度200,000/Lの水溶液を調製し、MS agarをオートクレーブ後、約50℃に冷めたところに培地の1/1,000量添加した。) * 5: Composition in 1 liter of Mitis-Salivarius agar plate medium supplemented with bacitracin Mitis-Salivarius Agar
(Becton and Dickinson): 90 g / L
Bacitracin (Sigma Aldrich): 200U / L
(Bacitracin was prepared in advance as an aqueous solution having a 1,000-fold concentration of 200,000 / L, and after MS agar was autoclaved, it was cooled to about 50 ° C. and added to 1/1000 of the medium.)
外観安定性の評価方法:
サンプル(液体口腔用組成物)を満注量500mLの無色透明なPET容器(吉野工業所製)に450mL充填し、50℃恒温槽(三洋電機社製、MPR-311)に1ヶ月保存後の外観安定性を下記基準に則り、目視判定した。
外観安定性の評価基準:
◎:振とうしてもオリが全く認められない。
○:振とうした際にごく微小なオリが認められるが、問題ないレベルで
ある。
△:わずかなオリが認められる。
×:かなりのオリが認められる。 (III) Appearance stability (no tilt)
Appearance stability evaluation method:
The sample (liquid oral composition) is filled into a colorless and transparent PET container (manufactured by Yoshino Kogyo Co., Ltd.) having a filled volume of 500 mL, and stored in a 50 ° C. constant temperature bath (manufactured by Sanyo Electric Co., Ltd., MPR-311) for one month. The appearance stability was visually determined according to the following criteria.
Appearance stability evaluation criteria:
A: No orientation is observed even when shaken.
○: Although very small orientation is observed when shaken, it is at a level with no problem.
Δ: Slight orientation is observed.
X: Considerable orientation is recognized.
サンプル(液体口腔用組成物)約10mLを口に含み、30秒間すすいだ後、洗口後の使用感について下記の4段階で評価し、10名の平均点を次の基準に従い、◎、○、△、×で示した。
使用感の評価基準:
4点:渋味・苦味・異味がなかった。
3点:渋味・苦味・異味がほとんどなかった。
2点:渋味・苦味・異味がややあり、若干使用し難かった。
1点:渋味・苦味・異味がかなりあり、使用するのに支障があった。
使用感の判定基準:
◎:平均点3.5点以上4.0点以下
○:平均点3.0点以上3.5点未満
△:平均点2.0点以上3.0点未満
×:平均点2.0点未満 (IV) Feeling of use (no astringency, bitterness or taste)
About 10 mL of sample (composition for liquid oral cavity) was included in the mouth, rinsed for 30 seconds, and the feeling after use for mouthwash was evaluated in the following four stages. The average score of 10 persons was evaluated according to the following criteria. , Δ, ×.
Usability evaluation criteria:
4 points: No astringency, bitterness or off-flavor.
3 points: Almost no astringency, bitterness or off-taste.
2 points: Slightly astringent, bitter, and off-flavor, slightly difficult to use.
1 point: There was considerable astringency, bitterness, and off-taste, and there was a hindrance to use.
Criteria for use feeling:
◎: Average point 3.5 points or more and 4.0 points or less ○: Average point 3.0 points or more and less than 3.5 points △: Average point 2.0 points or more and less than 3.0 points ×: Average point 2.0 points Less than
塩化セチルピリジニウム(和光純薬工業社製)
塩化ベンゼトニウム(ハイアミン1622:ロンザジャパン社製)
ヒドロキシエチルセルロースジメチルジアリルアンモニウムクロリド
(商品名 セルコートL-200:アクゾノーベル社製)
(商品名 セルコートH-100:アクゾノーベル社製)
レオガードKGP(塩化O-[2-ヒドロキシ-3-(トリメチルアンモニオ)プロピル]ヒドロキシエチルセルロース:ライオン(株)製)
アネトール(和光純薬工業社製)
ポリオキシエチレン(100)硬化ヒマシ油(日光ケミカルズ社製)
ポリオキシエチレン(60)硬化ヒマシ油(日光ケミカルズ社製)
プロピレングリコール(旭硝子社製)
グリセリン(85%、阪本薬品工業社製)
キシリトール(ロケット・フルーレ社製)
ポリオキシエチレン(20)セチルエーテル
(商品名 エマレックス120、日本エマルジョン社製)
クエン酸(扶桑化学社製)
クエン酸ナトリウム(扶桑化学社製)
サッカリンナトリウム(大東化学社製)
ポリエチレングリコール400(日油社製) The main raw materials used in each example are as follows. The perfume composition A is as shown in Tables 5 to 11.
Cetylpyridinium chloride (manufactured by Wako Pure Chemical Industries, Ltd.)
Benzethonium chloride (Highamine 1622: Lonza Japan)
Hydroxyethylcellulose dimethyldiallylammonium chloride (trade name Cellcoat L-200: manufactured by Akzo Nobel)
(Product name Cell Coat H-100: manufactured by Akzo Nobel)
Leogard KGP (O- [2-hydroxy-3- (trimethylammonio) propyl] hydroxyethylcellulose chloride: manufactured by Lion Corporation)
Anethole (manufactured by Wako Pure Chemical Industries)
Polyoxyethylene (100) hydrogenated castor oil (Nikko Chemicals)
Polyoxyethylene (60) hydrogenated castor oil (Nikko Chemicals)
Propylene glycol (Asahi Glass Co., Ltd.)
Glycerin (85%, Sakamoto Pharmaceutical Co., Ltd.)
Xylitol (Rocket Fleure)
Polyoxyethylene (20) cetyl ether (trade name EMALEX 120, manufactured by Nippon Emulsion Co., Ltd.)
Citric acid (manufactured by Fuso Chemical)
Sodium citrate (manufactured by Fuso Chemical)
Saccharin sodium (Daito Chemical Co., Ltd.)
Polyethylene glycol 400 (manufactured by NOF Corporation)
塩化セチルピリジニウム 0.05%
塩化ベンゼトニウム 0.01
ヒドロキシエチルセルロースジメチルジアリルアンモニウムクロリド
(セルコートL-200) 0.01
アネトール 0.05
ポリオキシエチレン硬化ヒマシ油(100) 0.5
プロピレングリコール 3
グリセリン 4.5
キシリトール 3
クエン酸 0.03
クエン酸ナトリウム 0.25
サッカリンナトリウム 0.004
精製水 バランス
計 100.0%
(C)成分/[(A)成分+(B)成分]=0.71 [Prescription Example 1]
Cetylpyridinium chloride 0.05%
Benzethonium chloride 0.01
Hydroxyethylcellulose dimethyl diallylammonium chloride (Cellcoat L-200) 0.01
Anethole 0.05
Polyoxyethylene hydrogenated castor oil (100) 0.5
Propylene glycol 3
Glycerin 4.5
Xylitol 3
Citric acid 0.03
Sodium citrate 0.25
Saccharin sodium 0.004
Purified water balance
Total 100.0%
(C) component / [(A) component + (B) component] = 0.71
塩化ベンゼトニウム 0.01%
ヒドロキシエチルセルロースジメチルジアリルアンモニウムクロリド
(セルコートL-200) 0.01
アネトール 0.05
ポリオキシエチレン硬化ヒマシ油(100) 0.5
プロピレングリコール 3
グリセリン 4.5
キシリトール 3
クエン酸 0.03
クエン酸ナトリウム 0.25
サッカリンナトリウム 0.004
精製水 バランス
計 100.0%
(C)成分/[(A)成分+(B)成分]=2.5 [Prescription Example 2]
Benzethonium chloride 0.01%
Hydroxyethylcellulose dimethyl diallylammonium chloride (Cellcoat L-200) 0.01
Anethole 0.05
Polyoxyethylene hydrogenated castor oil (100) 0.5
Propylene glycol 3
Glycerin 4.5
Xylitol 3
Citric acid 0.03
Sodium citrate 0.25
Saccharin sodium 0.004
Purified water balance
Total 100.0%
(C) component / [(A) component + (B) component] = 2.5
塩化セチルピリジニウム 0.05%
ヒドロキシエチルセルロースジメチルジアリルアンモニウムクロリド
(セルコートL-200) 0.01
アネトール 0.05
ポリオキシエチレン硬化ヒマシ油(80) 0.5
プロピレングリコール 3
グリセリン 4.5
キシリトール 3
クエン酸 0.03
クエン酸ナトリウム 0.25
サッカリンナトリウム 0.004
精製水 バランス
計 100.0%
(C)成分/[(A)成分+(B)成分]=0.83 [Prescription Example 3]
Cetylpyridinium chloride 0.05%
Hydroxyethylcellulose dimethyl diallylammonium chloride (Cellcoat L-200) 0.01
Anethole 0.05
Polyoxyethylene hydrogenated castor oil (80) 0.5
Propylene glycol 3
Glycerin 4.5
Xylitol 3
Citric acid 0.03
Sodium citrate 0.25
Saccharin sodium 0.004
Purified water balance
Total 100.0%
(C) component / [(A) component + (B) component] = 0.83
塩化セチルピリジニウム 0.05%
ヒドロキシエチルセルロースジメチルジアリルアンモニウムクロリド
(セルコートL-200) 0.01
アネトール 0.05
ポリオキシエチレン硬化ヒマシ油(100) 0.5
プロピレングリコール 3
グリセリン 4.5
ポリエチレングリコール400 4
クエン酸 0.03
クエン酸ナトリウム 0.25
サッカリンナトリウム 0.004
精製水 バランス
計 100.0%
(C)成分/[(A)成分+(B)成分]=0.83 [Prescription Example 4]
Cetylpyridinium chloride 0.05%
Hydroxyethylcellulose dimethyl diallylammonium chloride (Cellcoat L-200) 0.01
Anethole 0.05
Polyoxyethylene hydrogenated castor oil (100) 0.5
Propylene glycol 3
Glycerin 4.5
Polyethylene glycol 400 4
Citric acid 0.03
Sodium citrate 0.25
Saccharin sodium 0.004
Purified water balance
Total 100.0%
(C) component / [(A) component + (B) component] = 0.83
Claims (7)
- エタノールを実質的に含有しない液体口腔用組成物に、(A)カチオン性殺菌剤及び(B)ヒドロキシエチルセルロースジメチルジアリルアンモニウムクロリドを配合すると共に、(C)アネトールを(C)成分/[(A)成分+(B)成分]が質量比として0.1~10となる範囲で併用し、かつ(D)多価アルコール及び/又は(E)非イオン性界面活性剤を配合したことを特徴とする液体口腔用組成物。 A liquid oral composition substantially free of ethanol is blended with (A) a cationic fungicide and (B) hydroxyethyl cellulose dimethyl diallylammonium chloride, and (C) anethole is added to component (C) / [(A). Component + (B) component] is used in a mass ratio of 0.1 to 10, and (D) a polyhydric alcohol and / or (E) a nonionic surfactant is blended. Liquid oral composition.
- (A)カチオン性殺菌剤が塩化セチルピリジニウムである請求項1記載の液体口腔用組成物。 (A) The composition for liquid oral cavity according to claim 1, wherein the cationic fungicide is cetylpyridinium chloride.
- (A)成分を0.01~0.1質量%配合した請求項1又は2記載の液体口腔用組成物。 The liquid oral composition according to claim 1 or 2, wherein 0.01 to 0.1% by mass of component (A) is blended.
- (C)成分を0.01~0.2質量%配合した請求項1、2又は3記載の液体口腔用組成物。 The liquid oral composition according to claim 1, 2 or 3, wherein 0.01 to 0.2% by mass of component (C) is blended.
- 組成物中のエタノール量が100ppm以下である請求項1乃至4のいずれか1項記載の液体口腔用組成物。 The liquid oral composition according to any one of claims 1 to 4, wherein the amount of ethanol in the composition is 100 ppm or less.
- エタノールを実質的に含有しない液体口腔用組成物に、(A)カチオン性殺菌剤及び(B)ヒドロキシエチルセルロースジメチルジアリルアンモニウムクロリドを配合すると共に、(C)アネトールを(C)成分/[(A)成分+(B)成分]が質量比として0.1~10となる範囲で併用し、かつ(D)多価アルコール及び/又は(E)非イオン性界面活性剤を配合し、前記液体口腔用組成物に(A)及び(B)成分を安定化配合する方法。 A liquid oral composition substantially free of ethanol is blended with (A) a cationic fungicide and (B) hydroxyethyl cellulose dimethyl diallylammonium chloride, and (C) anethole is added to component (C) / [(A). Component + (B) component] is used in a range of 0.1 to 10 as a mass ratio, and (D) a polyhydric alcohol and / or (E) a nonionic surfactant is blended, A method of stabilizing and blending the components (A) and (B) in the composition.
- 組成物中のエタノール量が100ppm以下である請求項6記載の方法。 The method according to claim 6, wherein the amount of ethanol in the composition is 100 ppm or less.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280016778.0A CN103458864B (en) | 2011-03-25 | 2012-03-01 | The method of component in liquid oral composition and stabilisation mixing said composition |
KR1020137022621A KR101936969B1 (en) | 2011-03-25 | 2012-03-01 | Liquid composition for oral cavity and method for stable addition of components to composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011067845A JP5853387B2 (en) | 2011-03-25 | 2011-03-25 | Liquid oral composition and method for stabilizing and blending ingredients into the composition |
JP2011-067845 | 2011-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012132747A1 true WO2012132747A1 (en) | 2012-10-04 |
Family
ID=46930494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/055170 WO2012132747A1 (en) | 2011-03-25 | 2012-03-01 | Liquid composition for oral cavity and method for stable addition of components to composition |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP5853387B2 (en) |
KR (1) | KR101936969B1 (en) |
CN (1) | CN103458864B (en) |
MY (1) | MY164603A (en) |
WO (1) | WO2012132747A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9192565B2 (en) | 2011-11-09 | 2015-11-24 | Colgate-Palmolive Company | Alcohol-free mouthwash |
WO2016089347A1 (en) * | 2014-12-01 | 2016-06-09 | Colgate-Palmolive Company | Increasing micro-robustness |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9125841B2 (en) * | 2013-02-26 | 2015-09-08 | Johnson & Johnson Consumer Inc. | Oral care compositions |
JP6413815B2 (en) * | 2015-02-06 | 2018-10-31 | ライオン株式会社 | Liquid oral composition |
KR102337307B1 (en) | 2017-04-10 | 2021-12-09 | (주)아모레퍼시픽 | Low irritating oral composition |
JP7143198B2 (en) * | 2018-12-03 | 2022-09-28 | サンスター株式会社 | oral composition |
WO2021167845A1 (en) * | 2020-02-18 | 2021-08-26 | Sunstar Americas, Inc. | Oral care composition |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001226244A (en) * | 1999-12-08 | 2001-08-21 | Lion Corp | Tooth paste composition |
JP2002187829A (en) * | 1999-12-08 | 2002-07-05 | Lion Corp | Dentifrice composition |
WO2007066497A1 (en) * | 2005-12-09 | 2007-06-14 | Lion Corporation | Dentifrice composition |
JP2008120753A (en) * | 2006-11-14 | 2008-05-29 | Sunstar Inc | Liquid composition for oral cavity |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3890395A (en) * | 1994-11-17 | 1996-06-17 | Warner-Lambert Company | Antimicrobial oral compositions |
JPH11255629A (en) * | 1998-01-08 | 1999-09-21 | Sunstar Inc | Composition for oral cavity |
JP2001139442A (en) * | 1999-08-27 | 2001-05-22 | Lion Corp | Liquid composition for oral cavity |
EP1236461A1 (en) * | 1999-12-08 | 2002-09-04 | Lion Corporation | Toothpaste compositions |
JP4985905B2 (en) * | 2005-07-29 | 2012-07-25 | ライオン株式会社 | Liquid oral composition and l-menthol precipitation prevention method |
JP5682283B2 (en) * | 2009-12-25 | 2015-03-11 | ライオン株式会社 | Liquid oral composition |
-
2011
- 2011-03-25 JP JP2011067845A patent/JP5853387B2/en active Active
-
2012
- 2012-03-01 WO PCT/JP2012/055170 patent/WO2012132747A1/en active Application Filing
- 2012-03-01 KR KR1020137022621A patent/KR101936969B1/en active IP Right Grant
- 2012-03-01 CN CN201280016778.0A patent/CN103458864B/en active Active
- 2012-03-01 MY MYPI2013003318A patent/MY164603A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001226244A (en) * | 1999-12-08 | 2001-08-21 | Lion Corp | Tooth paste composition |
JP2002187829A (en) * | 1999-12-08 | 2002-07-05 | Lion Corp | Dentifrice composition |
WO2007066497A1 (en) * | 2005-12-09 | 2007-06-14 | Lion Corporation | Dentifrice composition |
JP2008120753A (en) * | 2006-11-14 | 2008-05-29 | Sunstar Inc | Liquid composition for oral cavity |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9192565B2 (en) | 2011-11-09 | 2015-11-24 | Colgate-Palmolive Company | Alcohol-free mouthwash |
WO2016089347A1 (en) * | 2014-12-01 | 2016-06-09 | Colgate-Palmolive Company | Increasing micro-robustness |
US10537506B2 (en) | 2014-12-01 | 2020-01-21 | Colgate-Palmolive Company | Increasing micro-robustness |
Also Published As
Publication number | Publication date |
---|---|
KR101936969B1 (en) | 2019-01-09 |
CN103458864B (en) | 2016-08-17 |
JP5853387B2 (en) | 2016-02-09 |
KR20140007406A (en) | 2014-01-17 |
CN103458864A (en) | 2013-12-18 |
MY164603A (en) | 2018-01-30 |
JP2012201632A (en) | 2012-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5136797B2 (en) | Isopropylmethylphenol-containing liquid oral composition | |
JP4591680B2 (en) | Liquid oral composition | |
CN107875031B (en) | Oral biofilm remover and oral composition | |
JP4985905B2 (en) | Liquid oral composition and l-menthol precipitation prevention method | |
JP5853387B2 (en) | Liquid oral composition and method for stabilizing and blending ingredients into the composition | |
JP4957882B2 (en) | Ethanol-free mouthwash composition | |
JP5729252B2 (en) | Oral composition | |
JP6318487B2 (en) | Oral composition | |
JP5359546B2 (en) | Liquid oral composition | |
WO2018194111A1 (en) | Oral biofilm removing agent and oral composition | |
JP4873154B2 (en) | Liquid oral composition | |
JP2010143843A (en) | Liquid composition for oral cavity | |
JP5682283B2 (en) | Liquid oral composition | |
CN107205899B (en) | Liquid oral composition | |
JP5729391B2 (en) | Tooth surface adhesion inhibitor of periodontal disease-causing bacteria, oral biofilm formation inhibitor, and oral composition | |
JP5682264B2 (en) | Oral composition and tooth surface adhesion inhibitor for periodontal disease-causing bacteria | |
JP4952940B2 (en) | Liquid oral composition | |
WO2011077847A1 (en) | Emulsion-type liquid composition for oral cavity, and process for production thereof | |
KR101773227B1 (en) | Dentrifice composition | |
JP2013203676A (en) | Composition for oral cavity | |
CN109689016B (en) | Liquid oral composition | |
JP2013256466A (en) | Liquid composition for oral cavity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12764783 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20137022621 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1301005319 Country of ref document: TH |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12764783 Country of ref document: EP Kind code of ref document: A1 |